AbbVie Inc. $ABBV Shares Bought by Cinctive Capital Management LP

Cinctive Capital Management LP lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 33.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 39,816 shares of the company’s stock after purchasing an additional 9,956 shares during the period. Cinctive Capital Management LP’s holdings in AbbVie were worth $9,219,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its position in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC lifted its stake in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. boosted its holdings in shares of AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares during the period. Impax Asset Management Group plc purchased a new position in shares of AbbVie during the second quarter worth approximately $990,000. Finally, Foundations Investment Advisors LLC grew its position in shares of AbbVie by 10.4% during the second quarter. Foundations Investment Advisors LLC now owns 24,913 shares of the company’s stock worth $4,624,000 after acquiring an additional 2,346 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by company insiders.

AbbVie Price Performance

NYSE:ABBV opened at $219.73 on Friday. The firm has a market cap of $388.51 billion, a price-to-earnings ratio of 93.10, a price-to-earnings-growth ratio of 0.76 and a beta of 0.34. The firm’s fifty day moving average price is $224.33 and its 200 day moving average price is $224.67. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the firm earned $2.16 EPS. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase‑1 data for ABBV‑295 reported as encouraging — supports pipeline optionality beyond core brands and is constructive for long‑term revenue upside. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: AbbVie advanced a risankizumab dosing study, signaling continued investment in immunology — reinforces management’s growth strategy in a key therapeutic area. AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment
• Positive Sentiment: RBC Capital started coverage with an Outperform and $260 price target — a bullish institutional view that supports upside versus current levels. RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
• Positive Sentiment: Consensus analyst stance remains supportive (“Moderate Buy”), which provides a baseline of buy‑side conviction. AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Allergan Aesthetics‑affiliated providers earned top rankings in NY (beneficial for Allergan Aesthetics’ commercial reputation, but limited immediate impact on ABBV stock). New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row
• Neutral Sentiment: Features and listicles (e.g., halal/debt‑free stock roundup, retirement income pieces) mention AbbVie but are peripheral to near‑term price movement. Is AbbVie Inc. (ABBV) One of the Debt Free Halal Stocks to Buy?
• Neutral Sentiment: Market reports forecasting growth in bipolar‑depression therapies expand the market opportunity for psychiatric drugs broadly; indirect for AbbVie unless tied to specific assets. Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
• Negative Sentiment: Shareholder governance concern: reports that the AbbVie CEO’s pay package has spiked above $30M can weigh on sentiment and prompt selling by governance‑focused funds. J&J, AbbVie CEOs See Pay Spike to More Than $30M
• Negative Sentiment: Analyst debate about immunology competition and valuation creates two‑sided risk—some analysts lift targets on growth, others flag competition that could cap upside, encouraging short‑term profit‑taking. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks

Analysts Set New Price Targets

ABBV has been the subject of several research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Citigroup lowered their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Morgan Stanley increased their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.